biological activity | LDN193189 HCl is the hydrochloride salt of LDN193189, which is a selective inhibitor of BMP signaling, it inhibits the transcriptional activity of BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM and is 200-fold more selective for BMP than for TGF-β. |
in vitro study | LDN193189 can effectively inhibit the activation of Smad1, Smad5 and Smad8 mediated by BMP4, IC50 is 5 nM, it also effectively inhibited the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively. In addition, LDN193189 also has an inhibitory effect on the transcriptional activation induced by the persistently activated ALK2R206H or ALK2Q207D muteins. A recent study showed that in human arterial endothelial cells, LDN-193189 blocked the production of oxidative free radicals induced by oxidized LDL. |
in vivo studies | in carrying Ad.Cre conditional caALK2 transgenic mice 7 days after birth, LDN-193189 (3 mg/kg, I. P.) caused weak left tibia and fibula calcification, visible on day 13, the lesion was blocked on day 15 without causing weight loss or growth retardation, spontaneous fracture, decreased bone density, or behavioral abnormalities. LDN193189 formed a curved zebrafish embryo by inhibiting the signaling pathway induced by bone morphogenetic protein (BMP)6, and had no effect on vascular development. In mice with PCa-118b tumors, LDN-193189 treatment slowed tumor growth and reduced bone formation in tumors. In LDLR-/-mice, LDN-193189 inhibited the development of atheroma. In addition, LDN-193189 has an inhibitory effect on vascular inflammation, Osteogenic Activity and calcification. |
characteristics | cell permeability BMP receptor specific inhibitor. |